CD45RB is a novel molecular therapeutic target to inhibit Abeta peptide-induced microglial MAPK activation.

CD45RB is a novel molecular therapeutic target to inhibit Abeta peptide-induced microglial MAPK activation.

Microglial activation, characterized by p38 MAPK or p44/42 MAPK pathway signal transduction, occurs in Alzheimer's disease (AD). Our previous studies demonstrated CD45, a membrane-bound protein tyrosine phosphatase (PTP), opposed beta-amyloid (Abeta) peptide-induced microglial activation via in...

Full description

Bibliographic Details
Main Authors: Yuyan Zhu, Huayan Hou, William V Nikolic, Jared Ehrhart, Elona Rrapo, Paula Bickford, Brian Giunta, Jun Tan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2008-05-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2366070?pdf=render

Internet

http://europepmc.org/articles/PMC2366070?pdf=render

Similar Items